Phaseline

Companies › GRIN Therapeutics

GRIN Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 5 registered trials: 4 Phase 1, 1 Phase 3; Neurology, Gastroenterology, Other; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Radiprodil
Glutamate NMDA receptor; GRIN1/GRIN2B antagonist
GRIN1, GRIN2BPhase 3GRIN-related Neurodevelopmental Disorder; Healthy Adult Participants; GRIN-related Disorders; Hepatic Impairment …Nov 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07884734RadiprodilPhase 1Healthy Adult ParticipantsOtherOct 2026
NCT05818943RadiprodilPhase 1GRIN-related DisordersNeurologyNov 2026
NCT07224581RadiprodilPhase 3GRIN-related Neurodevelopmental DisorderOtherMay 2027
NCT07457229RadiprodilPhase 1Hepatic ImpairmentGastroenterologyMay 2027
NCT06392009RadiprodilPhase 1Tuberous Sclerosis ComplexOtherJun 2028

Targets

GRIN1 (1) GRIN2B (1)

Companies with the same targets

Syndeio Biosciences SHINKEI Therapeutics Aptinyx Johnson & Johnson (Janssen) Praxis Precision Medicines Arialys Australia atai Therapeutics Neuren Pharmaceuticals BnH Research SyneuRx International (Taiwan)

Companies built like this

Neuren Pharmaceuticals Aptinyx SHINKEI Therapeutics Syndeio Biosciences Dr. F. Köhler Chemie

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.